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ABSTRACT
A timely controlled release dosage form with minimization of transit time and pH effects of gastrointestinal tract for chronotherapy
of propranolol was developed. Ethylcellulose (EC) and Eudragit RS selected as the controlling membrane for drug-layering non-pareil
seeds (NP) or extrusion-spheronized pellets incorporated with matrix materials or osmogents were characterized in the simulated gastric
fluid (SGF) and pH change medium. Results demonstrated that when propranolol was layered on NP, Eudragit RS plasticized with 30%
triethylcitrate (TEC) coated at 15% level could adjust a lag time close to the reference but with a slower release rate after then, while EC
plasticized with HPMC could not delay drug release at a lag time close to the reference. Furthermore, EC incorporated with lactose coated
on the extrusion-spheronized pellets could adjust the lag time, but a release rate correspondingly decreased with increasing lag time. Nevertheless, coating Eudragit RS on matrix pellets as controlling membrane at different levels could adjust a desired lag time with a pulsatile
release pattern. However, the lag time adjusted was only within a 5 h range. Finally, coating Eudragit RS at different level on matrix pellets
containing various ratio of osmogent, NaCl or lactose, could effectively adjust a desired lag time as long as 15 h with a pulsatile release
pattern to accomplish the timely controlled release with minimization of the pH effects of gastrointestinal tract that could meet the clinical
need for chronotherapy of propranolol.
Key words: timely controlled release, lag time, ethylcellulose, Eudragit RS, osmogents

INTRODUCTION
Recently the concept of the chronopharmacokinetics
and chronotherapy of drugs has been extensively utilized in
clinical therapy for improving drug efficacy and minimizing
side effects and drug tolerance(1-3). To avoid developing
tolerance and to follow the innate circadian rhythm, a reasonable and generally acceptable rationale is to have a delivery
system capable of delivering drugs in a pulsatile fashion or
timely controlled release instead of a continuous manner
at predetermined time points and/or sites following oral
administration(4-7). For this purpose, many systems including
the time clock system have been developed using various
technique and functional polymers or additives(8-11). Press
coating technique disclosed by Ishino et al. is one of such
novel system that not only acts as a rate controlling system
but also delivers the drug in the gastrointestinal (GI) tract in
a time-controlled fashion as required(12).
* Author for correspondence. Tel/Fax: +886-2-23771942;
E-mail: mingsheu@tmu.edu.tw
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Oral pulsatile drug delivery systems applied to these
drugs often have a high first-pass effect or special chronopharmacological needs have been reviewed by Bussemer
et al.(13) and by Maroni et al.(14). Pulsatile drug delivery
systems can be classified into site-specific system, in which
the drug is released at the desired site within the intestinal
tract (e.g., the colon), or time-controlled devices, in which
the drug is released often after a well-defined time period.
Site-specific controlled release is usually controlled by environmental factors, like the pH or enzymes present in the
intestinal tract, whereas the drug release from time-controlled
systems is controlled primarily by the delivery systems that
provided with rupturable membrane layers, swellable/erodible membrane layers, increasingly permeable membrane
layers, or release-controlling plugs.
The incidence of many cardiovascular diseases varies
predictably in time over 24 h, i.e., in a circadian rhythm
fashion(15). A rapid increase in both acute myocardial infarction and systolic blood pressure has been reported in the
well-controlled studies on actual patients. In such cases,
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administration of a different kind of unit dosage form delivers
the drug in higher concentrations during the time of the
greatest need, typically during the early morning hours, and
in lesser concentrations when the need is less, such as during
late evening and early sleep hours. A pulsatile release system
was disclosed by U.S. application Ser. No. 09/778,645, which
includes a combination of two or three pellet populations,
each with a well-defined release profile and a plasma profile
was obtained which varies in a circadian rhythm fashion
following administration(16). Recently, several reviews have
been published to report drug delivery technologies for chronotherapeutic applications(17-22).
Propranolol is a β-adrenergic blocking agent and as such
is a competitive inhibitor of the effects of catecholamines
at beta-adrenergic receptor sites. The principal effect of
propranolol is to reduce the cardiac activity by diminishing or
preventing beta-adrenergic stimulation. Therefore, a delivery
system for circadian rhythm release of cardiovascular drug
propranolol in a timed and sustained release pattern was
designed and commercially available to provide a plasma
concentration-time profile, which varies according to physiological need during the day, i.e., mimicking the circadian
rhythm and severity/manifestation of a cardiovascular
disease(23). This timed and sustained release multi-particulate
dosage form, Innopran XL, comprised a propranolol core
with a first membrane of sustained release polymer and a
second membrane of mixture of water insoluble polymer and
enteric polymer (2nd or outer membrane), wherein the water
insoluble polymer and the enteric polymer may be present
at a weight ratio from 10:1 to 1:2. Since the lag time period
for the initiation of drug release was regulated by the enteric
(HPMCP, hydroxypropylmethyl cellulose phthalate) polymer
mixing with a sustained release polymer (EC, ethylcellulose),
the variations in the transit time of stomach and the pH value
in the intestinal tract will influence both lag time period and
subsequent sustained release rate. It was thought that development of a timed and sustained release membrane system with
minimization of pH effects in the GI tract would be beneficial in the design of a delivery system for circadian rhythm
release of drug propranolol. In this study, two water-insoluble
and pH-independent rate-controlling polymeric membranes
of EC and Eudragit RS were compared for timed controlled
release characteristics and pellet formulations were optimized
for pH-independency of pulsatile or sustained release pattern.

MATERIALS AND METHODS
I. Materials
Propranolol HCl (IPCA Laboratories Limited, India)
was used as the model drug in this study. EC was supplied as
aqueous dispersion (Surelease, Colorcon, UK) and powder
form (100 cps, Hercules, USA). Eudragit RS (Rohm Pharma
GMBH, Germany), supplied as either 30% aqueous dispersion (designated as Eudragit RS 30D) or powder form (designated as Eudragit RS 100), was used as the rate-controlling
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polymer. Triethyl citrate (TEC, Tokyo Chemical Industry
Corp., Japan) and Hydroxypropyl methylcellulose (HPMC,
Pharmacoat 606, Shin-Etsu, Japan) were selected as a pore
former and plasticizer. MCC (microscrystalline cellulose,
PH 101) was used with the aid of spheronization and
supplied by Wei-Ming Pharmaceutical Manufacturing Ltd.
Co. (Taipei, Taiwan). Talc (Matsumura Industrial Co., Ltd.,
Japan) was used as an anti-adhering agent. Non-pareil seeds
(NPs, mean size of 0.71 - 0.85 mm) were purchased from
Pack-System Corporation (Taiwan). De-ionized distilled
water (DDW) and 95% alcohol (Tobacco and Liquor Corp.,
Taiwan) were used as the solvent for preparing the coating
solution. Innopran XL (batch number: 1AB0025) was a
product of GlaxoSmithKline LLC.
II. Experimental Methods
(I) Preparation of Drug-Containing Pellets
Drug-containing pellets were prepared by either drug
solution layering onto NPs or extrusion-spheronization
method. For drug solution layering method, 1 kg of NPs were
charged into the chamber of a fluidized-bed granulator and
coater (Glatt Air Technologies, model GPCG-1, Germany)
and fluidized by opening the inlet air flap. When the outlet
air temperature reached the desired level, 10% propranolol in
alcohol was tangentially sprayed onto the fluidized NPs from
an atomized nozzle (1 mm, dia.) attached to a peristaltic pump.
During processing, the spraying rate and inlet air temperature were adjusted to maintain the outlet air temperature at a
desired range. When the spraying was finished, pellets were
dried at 50°C for another 5 min in the chamber. The detailed
processing conditions were listed in Table 1 and the formulation was listed in Table 2. For extrusion-spheronization
method, a total of 500 g mixture containing propranolol HCl
powder, MCC, and lactose (according to formulations listed
in Table 3-5) was mixed for 3 min in a planetary mixer. The
aqueous dispersion solution containing EC (Surelease) or
Eudragit RS was then gradually added in a period of 1 min
and the blending was continued for another 30 min. The wet
mass was immediately extruded in an extruder (Chuan Yung
Industrial Co., Taiwan) of cylinder type with a 0.8 mm orifice
screen. The resultant extrudes were spheronized at a speed of
800 rpm for 5 min on the crosshatched plate of 9 inches (dia,)
in a spheronizer (Shang-Yuh Machine Co., Ltd., Taiwan).
After spheronization, pellets were cured in a hot-air oven at
40°C for 10 h.
(II) Controlling-Release Film Coating of Drug-Containing
Pellets
Four hundred grams of propranolol-containing pellets
were placed into the chamber of a fluidized-bed granulator
and coater (Model GPCG-1, Glatt Air Techniques, Germany),
rotated at 200 rpm and fluidized by opening the inlet air flap.
A film dispersion was prepared by mixing Surelease® latex
or Eudragit RS 30D with plasticizer and talc (according to
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Table 1. The coating conditions for propranolol hydrochloride and various polymers in fluidized-bed processor
Polymer coating
Apparatus conditions
Inlet temp. (°C)

Drug coating

HPMC

ECHPMC

ECLactose

Surelease

Eudragit
RS 30D

Eudragit
RS 100

55

40

44-47

45-47

55

42-46

40-42

Outlet temp. (°C)

37-39

35-37

33-37

34-38

30-33

27-35

27-31

Spray rate (mL/min)

5-10

3-5

5-7

5-7

5-8

4-10

4-5

Spray pressure (psi)

10

10

10

10

10

10

10

Flap (%)

25

30

20-35

20-35

30

30-35

35

Nozzle orifice (mm)

1.0

1.0

1.0

1.0

1.0

1.0

1.0

Table 2. The formulation compositions for drug-layering NP coating with Eudragit RS 100 or ethylcellulose (EC) dissolved in alcohol solution
plasticized by triethyl citrate (TEC) or hydroxypropylmethyl cellulose (HPMC), respectively
Formulations

2A

2B

2C

Core (g, Non-pareil)
Non-pareil seed (NP)

500

Propranolol HCl

200

Coating
2.2:1 (10, 15);
1.8:1 (15, 20)

0:25 (5)#

EC:HPMC (% of NP)
Eudragit RS100 (g, % of NP)

30(6); 45(9); 60(12); 75(15)

30(6); 45(9); 60(12); 75(15)

--

TEC (g, % of polymer)$

6(20); 9(20); 12(20); 15(20)

9(30); 13.5(30); 18(30); 22.5(30)

--

Talc (g, % of polymer)

9(30); 13.5(30); 18(30); 22.5(30)

9(30); 13.5(30); 18(30); 22.5(30)

--

88.04 ± 0.70 (6%)*

57.84 ± 1.68 (6%)

22.82 ± 1.34 (10%)

65.83 ± 2.44 (9%)

27.40 ± 1.01 (9%)

10.95 ± 0.07 (15%)

32.06 ± 1.10 (12%)

13.70 ± 0.16 (12%)

13.08 ± 0.31 (15%)

15.89 ± 1.95 (15%)

6.88 ± 0.11 (15%)

10.76 ± 0.34 (20%)

0.05 ± 0.01 (6%)

0.51 ± 0.02 (6%)

0.43 ± 0.05 (10%)

0.47 ± 0.05 (9%)

0.95 ± 0.08 (9%)

0.54 ± 0.11 (15%)

0.93 ± 0.10 (12%)

1.69 ± 0.09 (12%)

0.76 ± 0.49 (15%)

1.27 ± 0.19 (15%)

2.30 ± 0.30 (15%)

0.97 ± 0.10 (20%)

Parameters

Initial release rate (%/h)

Lag time (h)

#

The added amount of HPMC in drug-layered solution that used to layer drug on the nonpareil seeds.
$
The added amount of TEC in the coating solution.
*Number in parenthesis indicates the coating % of membrane.

formulations listed in Table 2-5) in an amount of 10 - 40%
(w/w) polymer, and then the final solid content was adjusted
to 12.5% (w/w) by dilution with DDW. When the outlet
temperature reached a desired level, the dispersion of the film
polymer was tangentially-sprayed onto the fluidized pellets
from an atomizing nozzle (1 mm) attached to a peristaltic
pump. During processing, the spraying rate and inlet air
temperature were adjusted to maintain the outlet air temperature at 27-30°C. The spraying continued until the designated
amount of film polymer was applied according to formulations listed. Finally, the film-coated pellets were cured in a
hot-air oven for another 10 h at 40°C.
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(III) Dissolution Studies
The USP dissolution apparatus 2 (Model DT-610, Jasco
Spectroscopic, Japan) was used to measure the release of
propranolol from the coated pellets at an agitation speed of
100 rpm. The temperature of the dissolution medium was
maintained at 37 ± 0.5°C. The drug release was compared
in the simulated gastric fluid (SGF) without enzyme (pH
1.2) and the pH change medium (2 h in SGF, 1 h in pH 4.5
phosphate buffer (PBS), and then the rest time period in pH
6.8 PBS). Aliquots of 5 mL of sample were withdrawn for
the assay at predetermined time intervals and replaced with
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the same volume of fresh medium. Propranolol content was
determined on a UV/VIS spectrophotometer (Model V550,
Jasco Spectroscopic, Japan) at 263 nm after appropriate

Table 3. The formulation compositions for pellets prepared by
extrusion-spheronization method with MCC and lactose using EC and
lactose at two ratios of 3 : 1 and 2 : 1 applied as alcohol solution as
the controlling membrane with a separating layer of HPMC
Formulations

3A
400

400

Lactose monohydrate

400

400

MCC PH 101

200

200

PVP K30

10

10

25 (5)

25 (5)

EC:Lactose (% of NP)

3:1 (10; 15; 20)

2:1 (10; 15; 20)

Talc (g, % of polymer)

10

10

Coating
Pharmacoat 606 (g, % of NP)

Parameters
5.87 ± 0.90 (10%)* 8.22 ± 0.25 (10%)
Initial release rate (%/h)

(IV) Characterizations of Pulsatile Pattern

3B

Core (g, Extrusion and Spheronization)
Propranolol HCl

dilution with the dissolution medium. Each dissolution data
point was the mean of at least 3 individual trials. The assay
method was validated before implementation. The precision
(CV%) and accuracy (RE%) were 0.02 to 2.80% and -1.40 to
0.27% for intra-day runs and were 0.01 to 1.40% and -0.33
to 1.96% for inter-day runs, respectively, in a concentration
range of 0.5 to 100 μg/mL.

4.60 ± 0.90 (15%) 4.77 ± 0.13 (15%)
2.39 ± 0.08 (20%)

The lag time and initial release rate were characterized
from the drug release profiles measured in the SGF and in
the pH change medium to evaluate the pulsatile pattern for
various membrane compositions. The initial release rate
was calculated from the line slope of the first three points
in the drug release profile of plotting cumulative amount vs.
time. The lag time was estimated by extrapolating the linear
portion of cumulative vs. time plot to the time-axis. Mean
and standard variation (SD) were reported for at least triplicate. Statistical analysis of one-way analysis of variance
(ANOVA) was used to determine the statistical significance
on the initial release rate and the lag time, (PASW Statistics
ver. 18.0) with p < 0.05 being considered to be statistically
significant.

3.3 ± 0.11 (20%)

RESULTS

0.45 ± 0.20 (10%) 0.22 ± 0.11 (10%)
Lag time (h)

0.92 ± 0.08 (15%) 0.82 ± 0.10 (15%)
1.58 ± 0.11 (20%) 0.99 ± 0.07 (20%)

*

Number in parenthesis indicates the coating % of membrane.

The pH-dependency of propranolol release from Innopran XL was first examined and demonstrated in Figure 1. A
lag time of 3-5 h and then a sustained release of propranolol

Table 4. The formulation compositions for matrix pellets prepared by extrusion-spheronization method with matrix materials of EC in either
aqueous dispersion (Surelease, 10 and 20%) or alcoholic solution (20 and 50%) using Eudragit RS 30D plasticized with 20% TEC as the
controlling membrane without a separating layer of HPMC
Formulations

4A

4B

4C

4D

Core (g, Extrusion and Spheronization)
Propranolol HCl

400

MCC PH 101

250

®

Surelease (% of powder)

10

20

--

--

EC (acetone, % of powder)

--

--

20

50

Coating
Eudragit RS 30D (% of pellets)

20; 30; 40

TEC (% of polymer)

20

Talc (% of polymer)

40

Parameters

Initial release rate (%/h)

Lag time (h)

44.19 ± 0.10 (20%)*

47.19 ± 1.07 (20%)

44.79 ± 1.11 (20%)

50.94 ± 1.72 (20%)

39.60 ± 2.01 (30%)

36.50 ± 2.56 (30%)

23.50 ± 1.16 (30%)

39.35 ± 1.37 (30%)

24.40 ± 2.00 (40%)

16.07 ± 0.42 (40%)

15.90 ± 1.06 (40%)

19.93 ± 1.61 (40%)

1.22 ± 0.03 (20%)

1.23 ± 0.03 (20%)

0.82 ± 0.03 (20%)

1.17 ± 0.08 (20%)

1.98 ± 0.03 (30%)

2.04 ± 0.03 (30%)

1.92 ± 0.06 (30%)

1.86 ± 0.03 (30%)

2.89 ± 0.06 (40%)

2.74 ± 0.16 (40%)

4.41 ± 0.41 (40%)

3.34 ± 0.10 (40%)

*

Number in parenthesis indicates the coating % of membrane.
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Table 5. The formulation compositions for matrix pellets prepared by extrusion-spheronization method with the addition of either NaCl as
osmogent and solubility modifier or Lactose as osmogent using Eudragit RS (plasticized with 30% TEC) as the controlling membrane
Formulations

5A

5B

5C

5D

5E

5F

49 (5 : 1)$

42 (2.5 : 1)

29.4 (1 : 1)

49 (5 : 1)

49 (5 : 1)

58.8

NaCl (%)

9.8

16.8

29.4

9.8

9.8

--

MCC (%)

41.2

41.2

41.2

28.8

20.6

41.2

--

--

--

12.4

20.6

--

Core (g, Extrusion and Spheronization)
Propranolol (%)

Lactose (%)
Coating (%)

Eudragit RS30D (% of pellets)

20; 30; 40

TEC (% of polymer)

20

Talc (% of polymer)

20

Parameters
8.68 ± 1.18 (20%)* 14.32 ± 1.12 (20%) 22.89 ± 0.74 (20%) 16.32 ± 0.48 (20%) 20.85 ± 0.96 (20%) 78.66 ± 1.25 (20%)
Initial release rate
(%/h)

Lag time (h)

5.95 ± 0.14 (30%)

8.53 ± 0.47 (30%) 20.29 ± 1.72 (30%) 12.56 ± 0.33 (30%) 11.33 ± 0.54 (30%) 34.54 ± 0.87 (30%)

6.69 ± 0.29 (40%)

5.92 ± 0.46 (40%) 9.79 ± 0.25 (40%) 10.25 ± 1.19 (40%) 15.43 ± 0.56 (40%) 40.31 ± 1.69 (40%)

3.62 ± 0.21 (20%)

2.34 ± 0.30 (20%) 1.94 ± 0.16 (20%) 4.44 ± 0.07 (20%) 4.84 ± 0.28 (20%) 0.35 ± 0.05 (20%)

9.00 ± 0.45 (30%)

4.83 ± 0.46 (30%) 3.57 ± 0.22 (30%) 8.25 ± 0.18 (30%) 6.92 ± 0.47 (30%) 1.36 ± 0.11 (30%)

15.15 ± 0.18 (40%)

7.51 ± 0.82 (40%) 6.08 ± 0.29 (40%) 9.86 ± 0.04 (40%) 9.91 ± 0.04 (40%) 1.59 ± 0.07( 40%)

$

Number in parenthesis indicates the ratio of propranolol to NaCl.
Number in parenthesis indicates the coating % of membrane.

*

pH 1.2
pH 6.8
pH 4.5
pH change

Drug Released (%)

100

80

60

40

20

0
0

5

10

15

20

25

Time (h)

Figure 1. The release profiles of propranolol from Innopran XL in
various media, (¿) simulated gastric fluid (SGF, pH 1.2); (▲) pH 4.5
phosphate buffer solution (PBS); (■) pH 6.8 PBS; () the pH change
medium.

at a slower rate were observed in both SGF and pH 4.5 PBS.
However, a shorter lag time (~2 h) was noted when dissolution was conducted in pH 6.8 PBS and then propranolol was
released within a period of 24 h in a sustained manner. Similarly, the same period of lag time as that in SGF or pH 4.5
PBS was observed in the pH change medium (3.47 ± 0.11 h)
and then propranolol was completely released within 24 h
following the similar profile as that in pH 6.8 PBS (initial
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release rate, 10.49 ± 0.74%/ h).
Two water insoluble and pH-independent controlling
membrane materials of Eudragit RS 100 and EC dissolved
in organic solution plasticized with triethyl citrate (TEC) and
HPMC, respectively, at two levels were initially examined
for their controllability of the release patterns. Propranolol
HCl was solution-layered on NPs and then coated with these
two rate-controlling membrane materials using fluidizedbed coating system by following the procedure described in
Experimental section. The drug release profiles were evaluated in SGF and pH change medium to examine the dependency of the drug release and the lag time on the pH value of
the medium and results were illustrated in Figure 2. It demonstrated that the release profile in both media were similar
with an f2 value at least greater than 70 for all coating formulations examined (data not shown). However, the increase
in the amount of plasticizer TEC added with Eudragit RS
100 in alcoholic solution from 20 to 30% led to a longer lag
time and then a slower release rate for Eudragit RS plasticized with 30% TEC and coated at the same percentage as
the controlling membrane (Figure 2A vs. 2B). On the other
hand, no lag time was seen for those controlling membranes
composed of EC and HPMC at two different ratios, even
at increasing coating level. The integrity of EC membrane
also seemed to be enhanced with increasing the proportion
of HPMC added (1.8 : 1 vs. 2.2 : 1 as shown by Figure 2C).
Extrusion-spheronization method was applied to incorporate propranolol HCl with commonly used excipients such
as MCC and lactose for preparing pellets. The controlling
membrane composed of EC and lactose (also used as a pore
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former) at two ratios (EC : lac) of 3 : 1 and 2 : 1 was then
applied as alcohol solution on the pellets with a separating
layer of HPMC to minimize the migration of water soluble
drug into the controlling membrane during its coating. The
(A)
100

Drug Released (%)

80

60

40

6% RS100 pH 1.2
9% RS100 pH 1.2
12% RS100 pH 1.2
15% RS100 pH 1.2
9% RS100 pH change
12% RS100 pH change
15% RS100 pH change

20

release profiles were conducted in SGF and the pH change
medium to assess the dependency of the drug release and
the lag time on the pH value of the medium and results were
shown in Figure 3. The independence on the pH change
of medium was demonstrated by that the release profiles
conducted at the pH 1.2 solution and the pH change medium
were similar for the controlling membranes composed of
EC and lactose at two ratios (Figure 3A: EC : lac = 3 : 1
and Figure 3B: EC : lac = 2 : 1) with three coating levels
of 10, 15, and 20%. The lag time increased with increasing
the EC : lac ratio (3 : 1 vs. 2 : 1) and also with increasing
the thickness of the controlling membrane (10% < 15% <
20%). However, the release rate correspondingly decreases
either with increasing the EC : lac ratio (3 : 1 vs. 2 : 1) at the
same coating thickness or with increasing the thickness of
the controlling membrane at the same EC : lac ratio.
Extrusion-spheronization method was also applied to

0
0

5

10

15

20

25

Time (h)

100

80

80

60
Reference (pH change)
6% RS100 pH 1.2
9% RS100 pH 1.2
12% RS100 pH 1.2
15% RS100 pH 1.2
6% RS100 pH change
9% RS100 pH change
12% RS100 pH change
15% RS100 pH change

40
20
0
5

10

15

20

Drug Released (%)

Drug Released (%)

100

0

Reference (pH change)
10% (EC:Lac=3:1) pH 1.2
15% (EC:Lac=3:1) pH 1.2
20% (EC:Lac=3:1) pH 1.2
10% (EC:Lac=3:1) pH change
15% (EC:Lac=3:1) pH change
20% (EC:Lac=3:1) pH change

(A)

(B)

60

40

20

25

0

Time (h)

0

5

100

15

20

25

20

25

Reference pH change
10% (EC:Lac=2:1) pH change
15% (EC:Lac=2:1) pH change
20% (EC:Lac=2:1) pH change
10% (EC:Lac=2:1) pH 1.2
15% (EC:Lac=2:1) pH 1.2
20% (EC:Lac=2:1) pH 1.2

(B)
100

80

80

60
Reference pH change
15% (EC:HPMC=1.8:1) pH 1.2
20% (EC:HPMC=1.8:1) pH 1.2
10% (EC:HPMC=2.2:1) pH 1.2
15% (EC:HPMC=2.2:1) pH 1.2
15% (EC:HPMC=1.8:1) pH change
20% (EC:HPMC=1.8:1) pH change
10% (EC:HPMC=2.2:1) pH change
15% (EC:HPMC=2.2:1) pH change

40

20

0
0

5

10

15

20

Drug Released (%)

Drug Released (%)

10

Time (h)

(C)

60

40

20

25

Time (h)

Figure 2. The release profiles of propranolol from drug solution
layering NPs coated with the rate-controlling membrane composed of
either Eudragit RS 100 plasticized with TEC at two levels (A: 20% and
B: 30%) applied as alcohol solution at various coating levels (: 6%;
£¢: 9%; rp: 12%; sq: 15%) or ethylcellulose (EC) and Pharmacoat 606 (HPMC) in a ratio of 1.8 : 1 (: 15%; £¢: 20%) and 2.2 :
1 (rp: 10%; sq: 15%) applied as alcohol solution at two different
levels (C).
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Figure 3. The release profiles of propranolol from extrusion-spheronization pellets coated with the HPMC separating layer and the ratecontrolling membrane composed of ethylcellulose:lactose (A: EC :
Lac = 3 : 1; B: EC : Lac = 2 : 1) applied as alcohol solution at various
coating levels (: 10%; £¢: 15%; rp: 20%).
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incorporate propranolol HCl and MCC with matrix materials of EC in either aqueous dispersion (Surelease, 10 and
20%) or alcoholic solution (20 and 50%) for preparing
pellets to minimize the migration of water soluble drug
into the controlling membrane during membrane coating.
The controlling membrane composed of Eudragit RS 30D
plasticized with 20% TEC was then applied on the pellets
at different ratio without a separating layer of HPMC. The
release profiles were then examined in the pH 1.2 solutions
and the pH change medium for comparison and results were
listed in Figure 4. It demonstrates that the lag time and the
release rate after the lag time for all release profiles were
independent of the pH change of the medium, and the lag
time was delayed and the release rate was slightly slowed
down with increasing the coating level of the controlling
membrane of Eudragit RS.
The influence of the addition of either NaCl as osmogent and solubility modifier or lactose as osmogent in the
matrix of pellets with using Eudragit RS (plasticized with
30% TEC) as the controlling membrane on the lag time
and resulting release rate was compared at two dissolution

DISCUSSION
As demonstrated in Figure 1, the pH-dependency of
propranolol release from Innopran XL was obvious. This
is because that Innopran XL comprised a propranolol core
with a first membrane of a sustained release polymer and a
second membrane of a mixture of water insoluble polymer
and an enteric polymer (2nd or outer membrane). Since its
outer layer of coating membrane was composed of EC and
HPMCP and the inner layer was composed of the former
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media of the SGF and the pH change medium. Results were
revealed in Figure 5 and demonstrated that the drug release
of all profiles was independent of the pH change of the
medium. The increase in the amount of NaCl only, but not
lactose, and the increase in the coating level of the controlling membrane were found to disproportionally extend the
lag time to as long as 15 h and to result in a similar pulsatile
release pattern as compared to those pellets without adding
either NaCl or lactose in the formulation (Figure 5F).
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Figure 4. The release profiles of propranolol from extrusion-spheronization matrix pellets using A: Surelease 10%, B: Surelease 20%, C: EC 20%,
and D: EC 50% as binder and then coated with the rate-controlling membrane composed of Eudragit RS 30D at various coating levels (: 10%;
£¢: 20%; rp: 30%; sq: 40%).
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Figure 5. The release profiles of propranolol from extrusion-spheronization matrix pellets containing NaCl (A: 1/5; B: 1/2.5; C: 1/1; F: 0/0) and
lactose (D: 3/7; E: 5/5; F: 0/0) coated with the rate-controlling membrane composed of Eudragit RS30D at various coating levels (: 10 or 15%;
£¢: 20%; rp: 30%;sq: 40%).

only, the insolubility of both EC and HPMCP in those
media with lower pH value (SGF, pH 4.5 PBS, and first 2
h in SGF of pH change medium) was expectable to make
a longer period of lag time that was necessary for medium
to wet both membranes to initiate the release of propranolol
from Innopran XL. However, a shorter period of lag time
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should be expected when dissolution was conducted in
pH 6.8 PBS, the pH value of which could make the outer
membrane layer more hydrophilic as a result of neutralization of HPMCP leading to shorten the lag time. After a lag
time for wetting to initiate the drug release in pH 1.2 and
4.5 PBS, both inner and outer layers of membrane remained
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integrity as the rate-controlling membrane led to a sustained
release of propranolol from Innopran XL at a slower rate,
while it was the inner layer solely composed of EC as the
rate-controlling membrane in pH 6.8 PBS and the pH change
medium (the pH value was adjusted to 6.8 after 3 h) since
HPMCP in the outer layer of membrane should be soluble
to make rate-controlling ability residing on the inner layer
of membrane that was solely composed of water-insoluble
EC. It was concluded that the lag time to initiate a pulsatile
release of propranolol from Innopran XL should be expected
to depend on the transit time of dosage form in the GI tract,
and variations in pH value of the GI tract might complicate
the lag time and subsequent sustained release manner. It was
also rational to examine the pH dependency of the release
profile by comparing the drug release in the SGF and the pH
change medium.
Two water insoluble and pH-independent controlling
membrane materials of Eudragit RS100 and EC dissolved in
organic solution plasticized with TEC or HPMC, respectively,
at two levels were firstly coated on NPs solution-layered
with Propranolol HCl using fluidized-bed coating system
for their controllability of the release patterns. As expected,
the release profiles controlled by two water insoluble and
pH-independent membrane materials were independent of the
change of pH value in the media. However, it was due to the
integrity of controlling membrane of Eudragit RS enhanced
by the increase in the amount of plasticizer (TEC) added
with Eudragit RS 100 in alcoholic solution from 20 to 30%
leading to a longer lag time and then a slower release rate
for Eudragit RS plasticized with 30% TEC and coated at the
same percentage as the controlling membrane (Figure 2A vs.
2B). Nevertheless, no lag time was shown for those controlling membranes composed of EC and HPMC at two different
ratios, even with increasing coating level. Since the lag time
observed for the release from a water-soluble membrane was
closely related to the time necessary for media solution to wet
membrane, the addition of water soluble polymeric material
of HPMC seems to be able to increase the hydrophilicity of
hydrophobic EC membrane at these two ratios, leading to the
increase of wettability of EC membrane with shortening the
lag time. Furthermore, the hydrophilicity of EC membrane
also seems to be enhanced with increasing the proportion
of HPMC added (1.8 : 1 vs. 2.2 : 1 as shown in Figure 2C)
resulting in a faster release rate using EC : HPMC at the 1.8 : 1
ratio as the controlling membrane. However, the increase in
the hydrophilicity for the controlling membrane composed
of EC and HPMC at a 1.8 : 1 ratio caused the retardation in
the release rate not greater with increasing its thickness than
that at a higher ratio of 2.2 : 1. It was thus concluded that
Eudragit RS membrane plasticized with 30% TEC coated at
an amount of 15% was able to adjust a lag time close to that
for reference product but with a slower release rate after then,
while EC membrane plasticized with HPMC was not able to
delay the release of drug at a lag time closely similar to the
reference product.
Matrix pellets incorporated with propranolol HCl and
commonly used excipients such as MCC and lactose were
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prepared by extrusion-spheronization method. The controlling membrane composed of EC and lactose (also used as a
pore former) at two ratios (EC : lac) of 3 : 1 and 2 : 1 was then
applied as alcohol solution on the pellets with a separating
layer of HPMC to minimize the migration of water soluble
drug into the controlling membrane during its coating. The
independency on the pH change of medium was confirmed
by that the release profiles conducted at the pH 1.2 solution and the pH change medium are similar for the controlling membranes composed of EC and lactose at two ratios
(Figure 3A: EC : lac = 3 : 1 and Figure 3B: EC : lac = 2 : 1)
with three coating levels of 10, 15, and 20%. The lag time was
observed to increase with increasing the EC : lac ratio (3 : 1
vs. 2 : 1) and with increasing the thickness of the controlling
membrane (10% < 15% < 20%). However, the release rate
correspondingly decreases either with increasing the EC : lac
ratio (3 : 1 vs. 2 : 1) at the same coating thickness or with
increasing the thickness of the controlling membrane at the
same EC : lac ratio. Since lactose was water soluble, it was
recognized as a pore former and a hydrophilic additive when
added with water insoluble material of EC as the controlling
membrane. Therefore, the increase in the amount of lactose
incorporated into the EC controlling membrane was expected
to increase its porosity that would enhance the release rate
and also to increase its wettability that would shorten the lag
time. It was concluded that the controlling membrane of EC
incorporated with lactose coated on the pellets manufactured
by extrusion-spheronization method is able to adjust the lag
time pattern by coating at different level, but resulting in a
release rate correspondingly decreasing with increasing lag
time, of which the lag time was shorter and the release rate
was slower than that for the reference product.
Pellets containing propranolol HCl and MCC with matrix
materials of EC in either aqueous dispersion (Surelease, 10
and 20%) or alcoholic solution (20 and 50%) were also
prepared by extrusion-spheronization method. The controlling membrane composed of Eudragit RS 30D plasticized
with 20% TEC was then applied on the pellets at different
ratio without a separating layer of HPMC. Their release
profiles in Figure 4 demonstrated that the lag time and the
release rate after the lag time for all release profiles were
independent of the pH change of the medium, and the lag
time was delayed and the release rate was slightly slowed
down with increasing coating level of the controlling
membrane of Eudragit RS. The release patterns for those
pellets using two different forms of EC as the matrix material with the same controlling membrane of Eudragit RS
were similar demonstrating that the release of propranolol
was mainly controlled by the diffusion across its controlling membrane of Eudragit RS. However, with increasing
the content of matrix material in the pellets for both forms
of EC, only the lag time slight increased but the release
rate similarly remianed at the same coating level of the
controlling membrane. Furthermore, all those release profiles
showed a shorter lag time and the release after the lag time in
a more pulsatile pattern than that for the reference product.
It was concluded that using Eudragit RS as the controlling
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membrane at different coating level is able to adjust a lag
time of desire with a pulsatile release pattern to accomplish
the timely controlled release independent of the pH change.
However, the lag time could be adjusted only within a range
of 5 h, that would be not so practical to meet the requirements
for longer lag time in clinics.
The addition of either NaCl as osmogent and solubility
modifier or lactose as osmogent in the matrix of pellets with
using Eudragit RS (plasticized with 30% TEC) as the controlling membrane was examined for their influence on the lag
time and resulting release rate at two dissolution media of
the pH 1.2 solution and the pH change medium. Results
shown in Figure 5 demonstrated that the drug release of all
profiles was independent of the pH change of the medium.
The increase in the amount of both additives (the ratio of
drug to additive decreases), either NaCl or lactose, and the
increase in the coating level of the controlling membrane
were found to disproportionally extend the lag time to
as long as 15 h, but to result in a similar pulsatile release
pattern as compared to those pellets without adding either
NaCl or lactose in the formulation (Figure 5F). The extension of the lag time with increasing the coating level was
rationally attributed to the increase in the thickness (h) of the
controlling membrane that would regulate the lag time (tL)
as theoretically predicted (tL=h2/6D)(11). On the other hand,
the decrease of the lag time with increasing extent of NaCl or
lactose (decreasing ratio of drug to additives) was assumed
to be a result of increasing osmotic effect with increasing
the amount of NaCl or lactose, of which the influx of water
from the medium into pellets was promoted leading to the
shortening of the lag time. There exists the osmotic effect
for the controlling membrane of Eudragit RS simply because
it was water insoluble polymeric material as to possess the
semi-permeable character.
Furthermore, as shown in Figure 5A, 5B and 5C, the
increased extent of the release rate was observed for those
pellets containing NaCl with increasing added NaCl amount
at the same coating level of the controlling membrane,
while it was observed that the decrease of release rate with
increasing coating level of the controlling membrane at
the same level of NaCl amount. The former phenomenon
was explainable similarly by the osmotic effect of NaCl
(being as an osmogent) promoting the drug release rate
for the same coating level of the controlling membrane.
According to theoretical equation describing diffusion
through membrane at sink condition : dQ/dt = (DK/h)*Cs, it
might also be partially attributed that the solubility for HCl
salt of propranolol (Cs) decreased with increasing the NaCl
amount (not for lactose) in the matrix pellets as a result of
common ion effect. The latter phenomenon is simply due
to the release rate is a reciprocal function to the thickness
(h) of the controlling membrane at the same level of NaCl
according to the above equation. Nevertheless, simply being
as an osmogent, the decreased extent of the release rate
from those pellets containing increasing amount of lactose
added would not be as significant as that for those pellets
containing increasing NaCl amount at the same coating level
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(Figure 5D and 5E). It was concluded that using Eudragit
RS as the controlling membrane at different coating level
and the addition of osmogent in the pellet formulation are
able to effectively adjust a lag time of desire for as long as
15 h with a pulsatile release pattern to accomplish the timely
controlled release membrane system with the minimization
of the pH effects of GI tract that could meet the practical
need in clinics.

CONCLUSIONS
In conclusion, matrix pellets that incorporated propranolol with osmogents, NaCl or lactose with a timely controlled
release independent of the pH change that could meet the
practical need in clinics for chronotherapy of propranolol
was developed. A timely and sustained release of the in vitro
dissolution profile in the pH change medium was demonstrated to be similar to that for Innopran XL but with less
dependency on the pH chang that might be encountered
during in vivo transits in the GI tract. However, independency of in vivo release profile on the pH change in the GI
tract will be confirmed in the future.
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